Literature DB >> 20598727

Characterization of varicella-zoster virus-encoded ORF0 gene--comparison of parental and vaccine strains.

Tetsuo Koshizuka1, Megumi Ota, Koichi Yamanishi, Yasuko Mori.   

Abstract

The varicella-zoster virus (VZV) Oka vaccine strain (vOka) differs from the parental strain (pOka) at several amino acid positions, but the mutations responsible for the attenuation of vOka have not been clearly defined. The ORF0 of vOka carries some of the mutations. Although we found that the ORF0 of both strains was incorporated into virus particles, the C-terminal region of vOka ORF0 was presented on the virion surface and was N-glycosylated, suggesting that the mutation in vOka ORF0 changes it into a novel envelope glycoprotein. In a mutant virus in which pOka ORF0 was replaced by vOka ORF0, the molecular weight of ORF0 was altered, but the plaque size was not. In addition, a pOka recombinant virus lacking the hydrophobic domain of ORF0 grew equally well as the wild-type virus, indicating that the mutation in ORF0 is not by itself sufficient for the attenuation of the vOka virus. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598727     DOI: 10.1016/j.virol.2010.06.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry.

Authors:  Akiko Kawabata; Hiroko Oyaizu; Takahiro Maeki; Huamin Tang; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Humanization of Murine Neutralizing Antibodies against Human Herpesvirus 6B.

Authors:  Bochao Wang; Mitsuhiro Nishimura; Yuji Maekawa; Toshiya Kotari; Toshiomi Okuno; Yasuko Mori
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

3.  Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  Curr Clin Microbiol Rep       Date:  2016-09-09

4.  Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein.

Authors:  Naoki Inoue; Misato Matsushita; Yoshiko Fukui; Souichi Yamada; Mihoko Tsuda; Chizuka Higashi; Keiko Kaneko; Hideki Hasegawa; Toyofumi Yamaguchi
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

5.  The varicella-zoster virus ORFS/L (ORF0) gene is required for efficient viral replication and contains an element involved in DNA cleavage.

Authors:  Benedikt B Kaufer; Benjamin Smejkal; Nikolaus Osterrieder
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

6.  Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax.

Authors:  Jong Ik Kim; Gyoo Seung Jung; Yu Young Kim; Ga Young Ji; Hyung Seok Kim; Wen Dan Wang; Ho Sun Park; Song Yong Park; Geun Hee Kim; Shi Nae Kwon; Keon Myung Lee; Jin Hyun Ahn; Yeup Yoon; Chan Hee Lee
Journal:  Virol J       Date:  2011-12-16       Impact factor: 4.099

7.  The Structures and Functions of VZV Glycoproteins.

Authors:  Stefan L Oliver
Journal:  Curr Top Microbiol Immunol       Date:  2021-11-04       Impact factor: 4.737

8.  The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Authors:  Geoffrey A Peters; Shaun D Tyler; John E Carpenter; Wallen Jackson; Yasuko Mori; Ann M Arvin; Charles Grose
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

9.  Analysis of IE62 mutations found in Varicella-Zoster virus vaccine strains for transactivation activity.

Authors:  Hyemin Ko; Gwang Myeong Lee; Ok Sarah Shin; Moon Jung Song; Chan Hee Lee; Young Eui Kim; Jin-Hyun Ahn
Journal:  J Microbiol       Date:  2018-06-01       Impact factor: 2.902

10.  Human Herpesvirus-6 U14 Induces Cell-Cycle Arrest in G2/M Phase by Associating with a Cellular Protein, EDD.

Authors:  Junko Mori; Akiko Kawabata; Huamin Tang; Kenjiro Tadagaki; Hiroyuki Mizuguchi; Kazumichi Kuroda; Yasuko Mori
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.